David E Ost1, Jiangong Niu2, Hui Zhao2, Horiana B Grosu3, Sharon H Giordano2. 1. Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX. Electronic address: dost@mdanderson.org. 2. Department of Health Services Research, MD Anderson Cancer Center, Houston, TX. 3. Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX.
Abstract
BACKGROUND: Guidelines for recurrent malignant pleural effusions (MPEs) recommend definitive procedures, such as indwelling pleural catheters (IPCs) or pleurodesis, over repeat thoracentesis. We hypothesized that many patients have multiple thoracenteses rather than definitive procedures and that this results in more procedures and complications. METHODS: Retrospective cohort study using SEER-Medicare data from 2007 to 2011. Patients 66 to 90 years of age with an MPE were included. The primary outcome was whether patients with rapidly recurring MPE, defined as recurrence within 2 weeks of first thoracentesis, received guideline consistent care. Guideline consistent care was defined as a definitive second pleural procedure. RESULTS: Thoracentesis for MPE was performed in 23,431 patients. A second pleural procedure because of recurrence was required in 12,967 (55%). Recurrence was rapid in 7,565 (58%) of the 12,967 patients that had a recurrence. Of the 7,565 patients with rapid recurrence, 1,811 (24%) received guideline consistent care. Definitive pleural procedures compared with repeat thoracentesis resulted in fewer subsequent pleural procedures (0.62 vs 1.44 procedures per patient, respectively; P < .0001), fewer pneumothoraxes (< 0.0037 vs 0.009 pneumothoraxes per patient, respectively; P = .001), and fewer ED procedures (0.02 vs 0.04 ED procedures per patient, respectively; P < .001). Repeat thoracentesis and IPCs resulted in fewer inpatient days compared with chest tube or thoracoscopic pleurodesis (0.013 vs 0.013 vs 0.085 vs 0.097 inpatient days per day of life, respectively; P < .001). CONCLUSIONS: Guideline consistent care using definitive procedures compared with repeat thoracentesis was associated with fewer subsequent procedures and complications; however, pleurodesis resulted in more inpatient days.
BACKGROUND: Guidelines for recurrent malignant pleural effusions (MPEs) recommend definitive procedures, such as indwelling pleural catheters (IPCs) or pleurodesis, over repeat thoracentesis. We hypothesized that many patients have multiple thoracenteses rather than definitive procedures and that this results in more procedures and complications. METHODS: Retrospective cohort study using SEER-Medicare data from 2007 to 2011. Patients 66 to 90 years of age with an MPE were included. The primary outcome was whether patients with rapidly recurring MPE, defined as recurrence within 2 weeks of first thoracentesis, received guideline consistent care. Guideline consistent care was defined as a definitive second pleural procedure. RESULTS: Thoracentesis for MPE was performed in 23,431 patients. A second pleural procedure because of recurrence was required in 12,967 (55%). Recurrence was rapid in 7,565 (58%) of the 12,967 patients that had a recurrence. Of the 7,565 patients with rapid recurrence, 1,811 (24%) received guideline consistent care. Definitive pleural procedures compared with repeat thoracentesis resulted in fewer subsequent pleural procedures (0.62 vs 1.44 procedures per patient, respectively; P < .0001), fewer pneumothoraxes (< 0.0037 vs 0.009 pneumothoraxes per patient, respectively; P = .001), and fewer ED procedures (0.02 vs 0.04 ED procedures per patient, respectively; P < .001). Repeat thoracentesis and IPCs resulted in fewer inpatient days compared with chest tube or thoracoscopic pleurodesis (0.013 vs 0.013 vs 0.085 vs 0.097 inpatient days per day of life, respectively; P < .001). CONCLUSIONS: Guideline consistent care using definitive procedures compared with repeat thoracentesis was associated with fewer subsequent procedures and complications; however, pleurodesis resulted in more inpatient days.
Authors: V B Antony; R Loddenkemper; P Astoul; C Boutin; P Goldstraw; J Hott; F Rodriguez Panadero; S A Sahn Journal: Eur Respir J Date: 2001-08 Impact factor: 16.671
Authors: J B Putnam; R W Light; R M Rodriguez; R Ponn; J Olak; J S Pollak; R B Lee; D K Payne; G Graeber; K L Kovitz Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker Journal: Chest Date: 2005-03 Impact factor: 9.410
Authors: Y C Gary Lee; Michael H Baumann; Nick A Maskell; Grant W Waterer; Tam E Eaton; Robert J O Davies; John E Heffner; Richard W Light Journal: Chest Date: 2003-12 Impact factor: 9.410
Authors: Lucía Ferreiro; Juan Suárez-Antelo; José Manuel Álvarez-Dobaño; María E Toubes; Vanessa Riveiro; Luis Valdés Journal: Can Respir J Date: 2020-09-23 Impact factor: 2.409
Authors: Audra J Schwalk; David E Ost; Sahara N Saltijeral; Henriette De La Garza; Roberto F Casal; Carlos A Jimenez; Georgie A Eapen; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jack Lee; Yasir Elamin; Jianjun Zhang; Jack A Roth; Stephen Swisher; John V Heymach; Horiana B Grosu Journal: Chest Date: 2020-11-17 Impact factor: 9.410